Ä¢¹½´«Ã½

Country websites

multiFiltratePRO

Our multiÄ¢¹½´«Ã½‘modality team player

The multiFiltratePRO has been carefully designed and equipped with a wide range of features intended to support your team in ICU patient care and offer you state-of-the-art therapies. Our device builds on extensive experience with the multiFiltrateÌýand the successfully established CiÄ¢¹½´«Ã½‘Ca regional citrate anticoagulation.1Ä¢¹½´«Ã½‘12

Focusing on your needs

Many critically ill patients in intensive care units (ICUs) are suffering from multi-organ failure and they depend on reliable application of organ support therapies.13

The multiFiltratePRO offers a wide range of therapeutic applications, mostly in intensive care, such as:

* Legal manufacturer of multiECCO2RÌýis EUROSETS S.r.l., Italy. Ä¢¹½´«Ã½ Deutschland GmbH is a distributor of multiECCO2RÌýin selected countries.

With the multiFiltratePRO, Ä¢¹½´«Ã½ aims to fulfill the requirements of ICU patients as thoroughly as possible, turning it into the ideal team player for your ICU.

Count on us to support you all the way Ä¢¹½´«Ã½“ from the initial implementation of CKRT into your clinical practice to the point of everyday questions in routine application. If you need any help setting up a treatment on the multiFiltratePRO, have a question during an ongoing CKRT treatment or have any technical questions, just call your local support hotline or Ä¢¹½´«Ã½ representative.

You will have access to a wide range of clinical support from experienced application specialists and our professional sales teams. Diagnostic programs specific to the device as well as our well-trained technicians are the basis for reliable device availability.

Expert meetings, workshops for physicians, and regular educational courses for nurses are optional services we offer to provide you with additional knowledge to apply efficient CKRT.

Explore the multiFiltratePRO

Related content

1ÌýWeidhase L et al. Plos One 2019; 14:e0215823

2ÌýEichhorn T et al. Blood Purif 2017; 44:260-266

3ÌýWeidhase et al. Crit Care 2020; 24:644

4ÌýHafner S et al. J Intensive Care 2015; 3:35

5ÌýBianchi NA et al. Blood Purif 2020; 49:567-575

6ÌýKalb R et al. Ther Apher Dial 2013; 17:202-212

7ÌýZarbock A et al. JAMA 2020;324:1629-1639

8ÌýMorgera et al. Crit Care Med 2009;37:2018-2024

9ÌýSlowinski T et al. Crit Care 2015; 19:349

10ÌýHoullé-Veyssière et al. Intensive Crit Care Nurs 2016; 36:35-41

11ÌýLink A et al. Crit Care 2012; 16:R97

12ÌýHuguet M et al. Int J Artif Organs 2017; 40:676-682

13ÌýICNARC. Case Mix Programme Summary Statistics 2019-20, www.icnarc.org/Our-Audit/Audits/Cmp/Reports/Summary-Statistics, accessed April 2021